Santa Clarita-based Specialty Laboratories Inc. appointed a new head of its board of directors Thursday, following the resignation of its chairman, who left because of increased duties with another firm.
Specialty Laboratories is a clinical laboratory for more than 10,000 hospitals and physicians in the United States.
Richard K. Whitney, a Specialty board member, was appointed chairman, replacing Richard E. Belluzzo, who resigned because of his responsibilities as CEO of Quantum Corp. Specialty’s board now consist of eight directors.
“On behalf of Specialty’s board and employees, I would like to thank Mr. Belluzzo for his many years of service to Specialty,” Whitney said in a statement. “Through his recent efforts, we strengthened Specialty’s board of directors with the addition of three new independent directors, completed the transition to our new facility and developed our strategic plan for 2005 and beyond.”
Whitney is an independent health care consultant and private investor, who recently served as chief financial officer of DaVita Inc., a provider of dialysis services.
“It’s been a privilege working with Specialty’s directors and officers over the last eight and a half years,” Belluzzo, said in a statement. “My decision to step down was necessary to provide me more time to focus on my other professional obligations. Specialty has executed an impressive turnaround in the last few years, and I’m confident that the company is well positioned to capitalize on the opportunities that lie ahead.”
Last summer, Specialty began moving into its recently-constructed three-story 187,262-square-foot office, research and development and laboratory facility on 13.8 acres on Tourney Road.
The firm was formerly divided among four separate buildings in Santa Monica. The company said its facility in Santa Clarita allowed it to consolidate its operations into a single building and increase its available space for future growth and capacity. The company anticipates the move will be complete early this year.
Shares of Specialty Laboratories fell 22 cents, or 2.2 percent, to $9.80 on the New York Stock Exchange on Thursday.
